A Costing Methodology for Hospital Package Rates

Start with what the case consumes, built as a bill of materials with the surgical team rather than derived from historical billing. Historical billing tells you what was charged, which is not the same as what was used — missed charges and generously rounded quantities both distort it. A twenty-minute conversation with the OT in-charge produces a more accurate list than a quarter of billing data.

Price the list at landed cost, including taxes that the hospital cannot recover as input credit. This is where hospitals routinely understate: an item costed at its ex-tax purchase price in a largely exempt business is being costed below what it actually costs the hospital.

Then handle variance deliberately. Some consumption is fixed per case, some varies with duration, and some appears only in complicated cases. Model the first two into the base and treat the third as a frequency-weighted addition — if a particular complication arises in a minority of cases and adds a known cost, its expected value belongs in the package price even though most patients will not incur it.

An operating theatre has a cost per hour, and a bed has a cost per day, and both need to be established before any package can be costed. Build the OT hourly rate from the resources committed to it while it runs: nursing and technician time, anaesthesia support, equipment depreciation and maintenance, sterilisation, utilities, and the turnaround time between cases that the theatre cannot sell to anyone else.

That last item is where most models understate. If a theatre runs a case in ninety minutes but consumes thirty minutes of cleaning and setup, the case has consumed two hours of theatre capacity. Costing it at ninety minutes systematically under-recovers, and the gap widens with every short case.

Bed-day cost follows the same logic, built from nursing ratio, housekeeping, dietary, utilities, and the ward's share of building cost. Different ward categories have genuinely different costs, particularly where nursing ratios differ, so a package that includes ICU days needs those days costed at ICU rates rather than an average bed-day figure.

Implants deserve separate treatment because they are high-value, highly variable, and often subject to price regulation. Where the National Pharmaceutical Pricing Authority has set ceiling prices for a device category, the hospital's realisable margin on that item is constrained, and a costing model that assumes a historical markup will overstate contribution.

The structural question is whether the implant sits inside the package or passes through separately. If it is inside, the package must be costed against the range of implants clinically appropriate for that procedure — and if surgeons can select from a range spanning a wide price band, the package carries the price risk. If it passes through, the package cost excludes it, but the hospital must be clear with the payer and the patient about that from the outset.

Where implants are inside the package, either constrain the choice to a defined set at defined prices, or price the package against the mix you actually observe rather than the cheapest option. Costing against the cheapest implant and letting surgeons select freely is a reliable way to lose money on high-volume procedures.

Overhead — administration, finance, IT, security, maintenance, marketing, and the building itself — has to land somewhere, and the allocation method changes which services look profitable. The three common approaches are allocation by revenue share, by activity volume, and by a step-down method that pushes support-department costs into clinical departments before allocating to services.

Revenue-share allocation is simple and systematically biased: it loads overhead onto high-priced services regardless of whether they consume more support, making them look worse and low-priced services look better than they are. Volume-based allocation has the opposite distortion. Step-down costing is more work and more defensible, because it traces support cost through the departments that actually use it.

The pragmatic answer for most hospitals is step-down for the material support departments and a simple basis for the rest, documented and applied consistently. Consistency matters more than theoretical purity — a method applied the same way every quarter lets you see change, while a method that improves each year makes trend analysis impossible.

Packages rarely fail loudly. They fail as a slow drift, and the drift has recognisable causes. Input prices rise while the rate stays fixed under a multi-year payer contract. Case mix shifts toward the complicated end because the hospital built a reputation and now receives the harder referrals. Length of stay creeps up. A surgeon switches to a costlier implant for good clinical reasons that nobody routed to finance.

The failure is invisible because package revenue is stable and the cost side is distributed across pharmacy, stores, OT, and ward budgets that each look normal. Nobody owns the intersection. By the time it shows up in departmental contribution, it has been running for several quarters.

The detection mechanism is a contribution-per-case view maintained per package, refreshed monthly against actual consumption rather than standard cost. HealUDoc analytics can bring actual consumable issues, theatre time, and length of stay together against package revenue, which turns a quarterly forensic exercise into a monthly report someone can read in ten minutes.

A package cost model that is built once and consulted at contract renewal is a historical document. The workable cadence is a monthly contribution review at the package level, a quarterly refresh of input costs, and a full rebuild of the model annually or whenever the clinical protocol for that procedure materially changes.

Ownership should be joint. Finance owns the model and the arithmetic; the clinical lead for that specialty owns the bill of materials and the protocol assumptions. A cost model that finance built alone will contain assumptions the surgeons would have corrected in five minutes, and it will lose credibility the first time it is challenged.

Make the output actionable rather than merely informative. Every package review should conclude with one of four decisions: hold the rate, renegotiate at renewal, change the clinical or supply protocol to reduce cost, or stop offering the package at that price. A review that ends without one of those has not finished.